论文信息 - Preclinical Development Dacomitinib ( PF-00299804 ) , an Irreversible Pan-HER Inhibitor , Inhibits Proliferation of HER 2-Ampli fi ed Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib - 字舞流文

Preclinical Development Dacomitinib ( PF-00299804 ) , an Irreversible Pan-HER Inhibitor , Inhibits Proliferation of HER 2-Ampli fi ed Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib

J. Christensen | R. Finn | C. Britten | D. Slamon | L. Anderson | C. Ginther | I. Taylor | David J Cohen | Amrita J. Desai | O. Kalous | D. Conklin | N. O’Brien | Neil A. O’Brien | Lee Anderson